Skip to Content <#contentTop>

If you are seeing this message, you may be experiencing temporary
network problems. Please wait a few minutes and refresh the page. If the
problem persists, you may wish to report it to your local Network Manager.

It is also possible that your web browser is not configured or not able
to display style sheets. In this case, although the visual presentation
will be degraded, the site should continue to be functional. We
recommend using the latest version of Microsoft or Mozilla web browser
to help minimise these problems.

    *
      My Cart </cart/shoppingcart>
    * My Profile </cgi-bin/myprofile>
    * Log In </>


  Wiley InterScience

</>	

    *
      HOME </>
    *
      ABOUT US </aboutus>
    *
      CONTACT US </contactus.html>
    *
      HELP </cgi-bin/help>


  JOURNALS

Home </>  /  Medicine and Healthcare </browse/?subject=MEDI>  / 
Oncology </browse/?subject=MD40>
 
International Journal of Cancer


    International Journal of Cancer

*See Also:*

    * International Journal of Cancer 1966-1995 </journal/112705918/home>

RSS feed for International Journal of Cancer </rss/journal/29331>What is
RSS? </cgi-bin/help?page=HELP_syndication#RSS>

Copyright © 2008 Wiley-Liss, Inc., A Wiley Company

 
 

    * Get Sample Copy
      </cgi-bin/vsample?PISSN=0020-7136&path_ok=/journal/29331/home>
    * Recommend to Your Librarian
      <javascript:mailTool(29331,%20'',%20'lib_');>
    * Save journal to My Profile
      </cgi-bin/createsavedtitle?ID=29331&path_ok=/journal/29331/home>
    * Set E-Mail Alert </cgi-bin/setalert?ID=29331&alert=on>
    * Email this page <http://www3.interscience.wiley.com/nojs.html>
    * Print this page <http://www3.interscience.wiley.com/nojs.html>

Published on behalf of
http://www.wiley.com/trackthrough?urlcode=456327
<http://www.wiley.com/trackthrough?urlcode=456327>
Go to Society Site <http://www.wiley.com/trackthrough?urlcode=456327>

Journal Home </journal/29331/home> | Funded Access
<http://www3.interscience.wiley.com/authorresources/funded_access.html> | News
</journal/29331/home/News.html>
Product Information
</journal/29331/home/ProductInformation.html> | Editorial Board
</journal/29331/home/EditorialBoard.html> | *For Authors* | Subscribe
<https://secure.interscience.wiley.com/jcatalog/subscribe.jsp?oid=29331&issn=0020-7136> | Advertise
</journal/29331/home/Advertise.html> | Contact
</journal/29331/home/Contact.html> | Online Submission
<http://mc.manuscriptcentral.com/ijc-wiley>


      /Issue Navigation/

Early View </journal/29331/earlyview> | Current Issue
</journal/29331/current> | 2008 </journal/ 29331 /issueyear
?year=2008> | 2007 </journal/ 29331 /issueyear ?year=2007> | 2006
</journal/ 29331 /issueyear ?year=2006> | 2005 </journal/ 29331
/issueyear ?year=2005> | 2004 </journal/ 29331 /issueyear
?year=2004> | ALL ISSUES (1996 - 2008) </journal/29331/toc>
 


        For Authors

For additional tools visit Author Resources
<http://www3.interscience.wiley.com/authorservices> - an enhanced suite
of online tools for Wiley InterScience journal authors, featuring
Article Tracking, E-mail Publication Alerts and Customized Research Tools.

    * Manuscript Submission Form <Conflict_of_interest_form.pdf>
    * Copyright Transfer Agreement <nscta.pdf>
    * Permission Request Form
      <http://www3.interscience.wiley.com/homepages/central/prf/USsprf.pdf>
    * Wiley's Journal Styles and EndNote
      <http://interscience.wiley.com/jpages/bonus/end_note_promo.html>
    * The National Institutes of Health Public Access Initiative
      <http://www3.interscience.wiley.com/authorresources/journal-man-sub.html#natins>



        Instructions to Authors


*Online Submission and Peer Review*
<http://mc.manuscriptcentral.com/ijc-wiley>

*/International Journal of Cancer/*
*Deutsches Krebsforschungszentrum*
*Im Neuenheimer Feld 242, F820*
*69120 Heidelberg, Germany*
*Telephone: +49-6221-42-4800*
*Fax: +49-6221-42-4809*
*intjcanc@dkfz.de*
*www.interscience.wiley.com*

The *International Journal of Cancer* (official journal of the
International Union Against Cancer?UICC) appears 24 times per year.
*International Journal of Cancer* invites submission of manuscripts
under a broad scope of topics relevant to experimental and clinical
cancer research and publishes original research articles, mini reviews,
forum papers, short reports, and letters to the editor. The article
categories within the journal are: carcinogenesis, cancer cell biology,
cancer genetics, infectious causes of cancer, tumor immunology, early
detection and diagnosis, epidemiology, and cancer therapy.

*SCOPE <#a1>*
 	Types of articles <#a2>
 		Research Articles <#a3>
 	 		Carcinogenesis <#a4>
 	 		Cancer Cell Biology <#a5>
			Cancer Genetics <#a6>
 	 		Infectious Causes of Cancer <#a7>
	 		Tumor Immunology <#a8>
 	 		Early Detection and Diagnosis <#a9>
 	 		Epidemiology <#a10>
 	 		Cancer Therapy <#a11>
		Mini Reviews <#a12>
 		Letters to the Editor <#a13>
		Short Reports <#a14>
*PRESENTATION OF MANUSCRIPTS <#b1>*
	Research Articles <#b2>
	Mini Reviews <#b3>
	Letters to the Editor <#b4>
	Short Reports <#b5>
	General Elements of Manuscripts <#b6>
		Sponsorship and Funding/Financial Disclosure <#b7>
		Gene Names <#b8>
		References <#b9>
		Figures <#b10>
		Electronic Supplementary Material <#b11>
*EDITORIAL PROCESS <#c1>*
*SUBMISSION PROCEDURE <#d1>*
	New Submissions <#d2>
		Required Documents for New Manuscripts <#d3>
	Submission of Revised Manuscripts <#d4>
*EDITORIAL DECISIONS <#d6>*
	Rejected Papers <#d7>
	Revisions Requested <#d8>
	Accepted Papers <#d9>
*PUBLICATION AND TECHNICAL INFORMATION <#e1>*
	Guidelines for Final Version of Accepted Papers <#e2>
		Text <#e3>
		Figures <#e4>
	Charges <#e5>
		Page charges <#e6>
		Color charges <#e7>
*CONTACT INFORMATION <#f1>*


            Types of Articles


            Research Articles

Full research papers should be as concise as possible, without
sacrificing documentation of results. For studies on humans, a clear
statement must be provided concerning informed consent, and that the
study was conducted after Human Experimentation Review by the relevant
committee. Research articles should fit within the categories outlined
below and meet the editorial standards stated.

The journal is pleased to offer a fast publication track for research
articles presenting superior novel findings and for studies of greatest
priority ranked against similar submissions. The ?Fast Track? articles
appear earlier than regular papers. Fast Track papers are chosen
specifically by the editors according to their judgment and upon the
recommendation of reviewers. Presentation of research articles <#b2>


            Carcinogenesis

Carcinogenesis includes studies on physical and chemical carcinogens,
metabolism, repair of carcinogen-modified DNA, molecular dosimetry, the
formation, identification and quantification of carcinogens from
exogenous and endogenous sources. Reports on mechanistic investigations
are particularly welcome and can include both animal and human studies.
The cancer-preventive potential of chemical, physical, or biological
reagents also fits into this section.
Return to Top <#top>


            Cancer Cell Biology

Analytical and functional data on tumor cell characterization (in vitro
and in vivo) and on tumor-stroma interactions are very welcome.
Immunohistochemical studies on tumor specimens should comprise reliable
characterization of the immune reaction with proof of antibody
specificity and selectivity. These data should be seconded by RNA
expression and/or functional studies demonstrating the reliability and
relevance of the histochemical findings. Confirmatory findings on
additional tumor types, stages, or sites without new functional,
diagnostic, or therapeutic implications are not within the scope of the
journal.
Return to Top <#top>


            Cancer Genetics

Genetic studies leading to the identification of factors and biochemical
pathways relevant for the pathomechanism of tumors are particularly
welcome. For studies concerning polymorphisms and cancer risk, a clear
explanation of the biological hypothesis underlying the investigation,
including possible biochemical pathways and functional relevance of
genetic polymorphisms should be given. In cases of newly identified
alleles, the potential functional relevance must be stated. Studies
about new diagnostic tools are also within the scope if they hold
promise of broad application. Regarding comprehensive data sets of
genetic profiling (microarray) studies, raw data must be in a publicly
available database that requires MIAME format (for example, "GEO" or
"Array Express") upon submission of a paper. Should expert reviewers of
the IJC request access to these primary data, authors need to provide
the confidential password that is supplied by the database provider.
Return to Top <#top>


            Infectious Causes of Cancer

Contributions to this section should cover novel observations on the
role of viral, bacterial, or parasitic infections in human cancers.
Mechanistic aspects concerning direct or indirect modes of infectious
carcinogens will be of particular interest. Functions of viral oncogenes
as well as the discovery of new viruses or other infectious pathogens
with growth-stimulating properties for infected cells or tissues will be
considered. Indirect modes of carcinogenesis by infections are clearly
of interest for the journal. Seroepidemiological and immunological
studies related to infectious carcinogens will be considered if they
present new data or demonstrate novel links between tumors and
infections. The development of vaccines directed against tumor-linked
infectious agents and their application is also of substantial interest.
We also consider submissions on oncolysis by infectious agents.
Return to Top <#top>


            Tumor Immunology

This section covers novel findings on the immunological relationship
between tumor and host, including all aspects of cellular and humoral
immunity directed at tumor and associated stromal cells. Experimental
and clinical studies based on in vivo, ex vivo and in vitro analysis
will be considered. Particularly welcome are studies on new and improved
preventive and therapeutic approaches exploiting immune effector
mechanisms, such as vaccines. The potential relevance of newly
identified tumor cell-associated T cell epitopes should be validated by
functional in vivo studies.
Return to Top <#top>


            Early Detection and Diagnosis

This section covers the area of predictive and diagnostic markers from
molecular biology studies. We invite papers that explore the development
and application of nucleic acid-based, protein-based, serological, and
other approaches that identify biomarkers linked to cancer as well as
the results of current investigations using other novel molecular probes
as diagnostic and prognostic indicators for cancer detection and therapy.
Return to Top <#top>


            Epidemiology

Studies in human populations providing evidence that i)
agents/exposures/host-factors pose a carcinogenic risk or are
protective, ii) attempt to establish their causal role, iii) identify
(sub-) populations at greatest risk, and iv) host-environment
interactions are welcome. These include molecular cancer epidemiology
approaches, in which advanced laboratory methods are integrated.
Randomized trials, case-control studies, cohort studies, studies of
screening and diagnostic tests and intervention studies will be
considered. Each manuscript should clearly state an objective or
hypothesis, the design and methods (including the source of patients or
participants with inclusion/exclusion criteria).
Return to Top <#top>


            Cancer Therapy

Reports on new advances in cancer therapy in humans are welcome,
especially the results of well-designed randomized trials. If the
authors are describing the results of a randomized controlled trial, we
recommend use of the style guidelines in describing the study population
(see JAMA 1996; 276:637-639). If the authors are describing the results
of observational studies of therapy, the standards applicable in
observational studies in epidemiology should be followed (see above). We
do not publish case reports.


            Mini Reviews

Though these are primarily commissioned by the Editors, exceptionally,
proposals will be considered and sent for peer review. Presubmission
inquiries describing the proposed articles must be sent before
submission. The Editors will then indicate whether the review is of
potential interest for the journal. Presentation of Mini Reviews <#b3>


            Forum

Forum papers present interesting and controversial topics in cancer
research, hypotheses, methods and applications. They are meant to
promote discussion and generate new ideas for further study.
Presentation of Forum Papers <#b10>


            Letters to the Editor

Comments on published papers and controversial issues, also including
negative data that are of general interest or that contradict commonly
accepted concepts or hypotheses, will be considered for publication as
Letters to the Editor. In the former case, the Editors may invite
letters containing pertinent and interesting observations concerning
cancer research in general, reports on new observations or pilot studies
that do not justify a full research article, or comments on published
papers will be considered for publication. In the latter case, the
Editors may invite the authors of the paper being questioned to respond.
Both letters may then be published, if found to be of interest to the
Editors. Presentation of Letters <#b4>


            Short Reports

Articles containing pertinent and interesting observations concerning
cancer research in general and reports on new observations or studies
that do not warrant publication as a full research article will be
considered for the Short Report section. These articles will undergo
full peer review. Presentation of Short Reports <#b5>


            Special Section Paper

These papers are commissioned by the Editors. Authors of Special Section
Papers will be given individual guidance in preparing their manuscripts.


            Presentation

Articles should be written in English (either British or American spelling).


            Research Articles

Research articles should be divided into these sections:

· Title Page (with short title, corresponding author contact information
?address, fax, and email?, three to five key words, abbreviations used,
and the appropriate journal category. Include 2 brief statements
describing the novelty and impact of your paper. Please ensure the fax
number is correct and list an alternate number if possible).
· Non-structured Summary/Abstract (maximum 250 words)
· Introduction
· Material and Methods
· Results
· Discussion
· Acknowledgments
· References
· Tables
· Figure Legends.
Please note that we cannot process your paper if the abstract or the
references do not conform to IJC style.


            Mini Reviews

Length should not exceed 4,000 words (3 printed journal pages) plus
figures and tables and approximately 50 references. Return to Top <#top>


            Presentation of Forum papers

Length should not exceed 4,000 words (3 printed journal pages) plus
figures and tables and approximately 50 references. Return to Top <#top>


            Letters to the Editor

Letters should begin with a title page (with the heading Letter to the
Editor and corresponding author contact information?address, fax, and
email). Length should not exceed 2,500 words. Return to Top <#top>


            Short Reports

Short Reports should begin with a title page (with the heading Short
Report and corresponding author contact information?address, fax, and
email). Length should not exceed 4,000 words.


            General Elements of Manuscripts


            Sponsorship and Funding/Financial Disclosure

The Acknowledgments section is an appropriate place to recognize
coworkers, indicate funding sources, and disclose information about
affiliations and potential conflicts of interest (for example,
commercial affiliations, patent-licensing arrangements). The
International Journal of Cancer subscribes to the guidelines published
by Davidoff et al. in the New England Journal of Medicine ^1 and to the
?Uniform Requirements for Manuscripts Submitted to Biomedical Journals.
^2 Authors must state all their sources of funding and any other
financial and personal relationships that might bias their work. If the
research reported in the manuscript has received partial or complete
funding from commercial sponsors, the authors must also include a
statement to that effect. The Editors reserve the right not to consider
a manuscript if a sponsor has asserted control over the authors' right
to publish their research results. Therefore, if the authors have a
potential financial or personal conflict of interest, they must submit
the Conflict of Interest <Conflict_of_interest_form.pdf> form.
Return to Top <#top>


            Gene Names

/Please mark all gene names in italics./ Only the gene names should be
written in italics, to distinguish them from gene products, gene
segments, clusters, families, complexes, or groups. Authors should only
use the official gene name as assigned by the respective gene
nomenclature committee.
Return to Top <#top>


            References

The Journal introduces a new reference style. If you use the program
EndNote, please note that you can download the IJC reference style sheet
<http://interscience.wiley.com/jpages/bonus/end_note_promo.html> from
the Wiley Interscience page. Please see examples below.
References are listed in a separate reference section immediately
following the text. All references must be verified by the corresponding
author who submits the manuscript to International Journal of Cancer.
Follow the style of the "Uniform Requirements for Manuscripts Submitted
to Biomedical Journals" ^2 for reference format and Index Medicus ^3 for
standard journal abbreviations (please see examples below). Number
references sequentially in the order cited in the text; do not
alphabetize. A reference cited only in a table or figure is numbered in
the sequence established by the first mention in the text of the table
or figure containing the reference.

Reference to a personal communication or to a manuscript categorized as
in preparation or submitted for publication is discouraged. However, if
such a reference is essential and refers to a written communication, the
source is cited parenthetically in the text (not in the reference
section) with the comment "unpublished data" or "personal
communication." Written permission from the source that is cited must be
sent to the Editorial Office. Reference to a paper accepted but not yet
published is listed in the reference section as "in press." "In press"
references must be updated by the authors as soon as publication data is
available.

Provide names of all authors in a reference when there are twelve or
fewer; if there are thirteen or more authors, list the first twelve,
followed by "et al."

Journal references shall include the specified information listed in the
following order: authors, article title and subtitle, journal
abbreviation, year, volume number in Arabic numerals, and inclusive pages:


Cohn KH, Ornstein DL, Wang F, LaPaix FD, Phipps K, Edelsberg C, Zuna R,
Mott LA, Dunn JL. The significance of allelic deletions and aneuploidy
in colorectal carcinoma: results of a 5-year follow-up study. Cancer
1997;79:233-44

Book references are listed as follows: authors, title, edition (if other
than the first), volume (if more than one), city, publisher, year, pages:

Sobin LH, Wittekind C, eds. TNM classification of malignant tumors, 5th
ed. New York: Wiley-Liss, 1997. 227p

When referencing a book chapter, the order changes as follows: authors
of the chapter, title of the chapter, "In:" editors/authors of the book,
title of the book, edition (if there are more than one), volume (if
there are more than one), city, publisher, year, and inclusive pages of
the chapter:

Luketich JD, Ginsberg RJ. Diagnosis and staging of lung cancer. In:
Johnson BE, Johnson DH. Lung cancer. New York: Wiley-Liss, Inc.,
1995:161-73.
Return to Top <#top>


            Figures

Authors should upload high-quality graphic data for figures. For use in
the peer review process, the Editorial office can use PPT, GIF, TIF,
JPG, and EPS files. Figures may be submitted in these formats. However,
the preferred format is tif or eps, which would be required when the
paper is accepted.


            Electronic Supplementary Material

Material that is not suitable for print publication such as very long
tables, database information, etc. can be published online as electronic
supplementary material. The final decision to do so, however, lies with
the Editors. Please submit camera-ready files for this material as it
will not be edited or altered in any way by the publisher.
Return to Top <#top>


            Editorial Process

All papers are assessed initially by the editors. A selection of papers
is then sent for external review to experts in the field. When a
decision is reached, a decision letter is sent to the authors by email
and the decision is posted on the IJC website
(http://mc.manuscriptcentral.com/ijc-wiley), where the comments of the
referees can also be viewed. Decision letters for papers not sent for
review are also sent by email and the decision also posted. To aid in
the peer review, we invite authors to suggest potential reviewers of
their paper (including address, fax, and email) in the cover letter, on
the submission form or in the online submission procedure. The authors
also have the option of naming nonpreferred reviewers. Receipt of a
manuscript is acknowledged by email.
We remind you that in submitting to International Journal of Cancer you
agree that your work is original in presentation and content and that
the work has neither been published elsewhere ? including being posted
on any site on the Internet ? nor is simultaneously under submission as
a complete paper with another journal.
Return to Top <#top>


            Submission Procedure


            New Submissions

Please submit all new manuscripts online. Individual files should be
uploaded for the text (doc or rtf format), tables (doc or rtf for text
or tif or eps for graphics) and figures (tif or eps). You do not need to
mail any copies. Launch your web browser and go to
http://mc.manuscriptcentral.com/ijc-wiley/. Check for an existing
account. If you are submitting for the first time, create a new account.
Follow the step-by-step instructions. Please note that the paper should
be submitted by or on behalf of the corresponding author so that he/she
receives all correspondence from the system.
At the end of a successful submission, a confirmation screen with a
manuscript number will appear and you will receive an e-mail confirming
that the manuscript has been received by the journal. If this does not
happen, please check your submission and/or contact technical support at
edsupport@wiley.com. Exceptionally, manuscripts can be submitted by
express mail or post, by email, or by ftp. Please contact the Editorial
Office by email regarding specific requirements.


            Required Documents for New Submissions

For new submissions we require the following documents, which can be
uploaded as a pdf file to the web or sent to us by fax or mail. The
required forms can be found on our website (
http://www3.interscience.wiley.com/cgi-bin/jabout/29331/ForAuthors.html
). They can be submitted by post, fax, email, or uploaded to the website
along with the manuscript.

*Cover Letter.* Please introduce your work in a cover letter in which
you address the following questions:

    * What is the aim of the study?
    * What are the significant and novel findings?
    * How do these findings relate to the present state of the field?


*Submission Form.* The Journal requires written consent of all authors
upon submission and again upon acceptance, verifying agreement with
content and presentation, and knowledge of submission to International
Journal of Cancer Financial Disclosure/Conflict of Interest Form.
Authors are requested to provide a statement concerning any commercial
sponsorship, commercial affiliations, stock/equity interests, or patent
licenses of potential financial disclosure with the work presented in
the submitted paper. Each author who has NOT checked the box on the
submission form indicating that he/she has no conflict of interest must
submit the *Conflict of Interest form.* The paper cannot be processed
until these forms are complete.. See section on Sponsorship and
Funding/Financial Disclosure <#b7> .
*Copyright Transfer Agreement* (signed by at least one author)
*Letter of Permission.* Permission is required from the appropriate
investigators when "personal communication" or "unpublished data" is
cited in the manuscript or from the publisher if previously published
material has been used in the manuscript.
Return to Top <#top>


            Submission of Revised Manuscripts

If you have been invited to submit a revised manuscript, please submit
it online via your author center. Instructions can be found there:
Enter your point-by-point responses to the associate editor and
reviewers separately at the ?View and Respond? button.
Upload two versions of the revised paper, one clean copy and another
with all changes underlined or marked. Please also reupload figures and
tables.


            Editorial Decisions


            Rejected Papers

Papers may be rejected either based on the opinions of the Editors or
based on the comments of external reviewers. Papers not reaching a high
enough level of priority or not fitting within the scope of the Journal
will be returned to authors without detailed comments. Only papers of
high priority will be considered. We will keep any glossy figures of
rejected manuscripts for 3 months and will return them upon request.
Return to Top <#top>


            Revisions Requested

If the Editors and the reviewers respond positively to a paper and are
interested in considering it further after additional work is included,
authors will be invited to resubmit the manuscript to IJC. A decision
letter will be sent by email containing the comments of the referees
and/or Editors. We ask that revisions are made within 3 months. Any
questions concerning the requested changes/additional work should be
addressed to the Editors by fax or email before submission of the
revised paper. Revised manuscripts may be returned to the original
reviewers for reassessment. Therefore, the review process of the revised
manuscript may take over a month in some cases. The Editors maintain the
option to reject a paper in a second or third round of revision if the
specific concerns have not been met or if the paper still does not meet
a high enough level of priority. Please always include the manuscript
number in any correspondence and the submission documents.

Return to Top <#top>


            Accepted Papers

When a manuscript is accepted for publication by the editors, it is sent
to the publisher (Wiley-Liss, Inc., Hoboken, NJ) for typesetting,
copyediting and printing. An electronic proof of the typeset and
copyedited version will be sent to the author for approval. We ask that
you report any changes immediately to the publisher. Manuscripts will be
held in the Heidelberg editorial office if outstanding materials are
required (submission form for final, accepted version of the paper,
conflict of interest form, and copyright transfer agreement if this has
not been submitted previously). Electronic proofs may take approximately
6 weeks to generate. The publisher, Wiley-Liss, Inc., may be contacted
with questions about proofs. See contact information.
Return to Top <#top>


            Publication and Technical Information


            Guidelines for Final Version of Accepted Papers

The final versions of accepted papers (text, tables and figures) should
be sent to the editorial office in electronic form, preferably as email
attachments to intjcanc@dkfz.de.


            Text


Software and Format. The latest version of Microsoft Word or Rich Text
Format (RTF) is preferred, although manuscripts prepared with other
operating systems and software may be accommodated. Do not use desktop
publishing software such as Aldus PageMaker or Quark XPress. If you
prepared your manuscript with one of these programs, including EndNote,
please export the text to a word processing format.
Return to Top <#top>


            Figures

Authors should upload high-quality graphic data for figures. The
required format is TIFF or EPS.

All color figures will be reproduced in full color in the online edition
of the journal at no cost to authors. Authors are requested to pay the
cost of reproducing color figures in print. When necessary to convey
essential scientific information authors are encouraged to submit color
illustrations. For best reproduction, bright, clear colors should be
used. Dark colors against a dark background do not reproduce well;
please place your color images against a white background wherever possible.
All print reproduction requires files for full color images to be in a
CMYK color space.

To ensure that your digital graphics are suitable for print purposes,
please go to RapidInspector? at
http://rapidinspector.cadmus.com/zwi/index.jsp . This free, stand-alone
software application will help you to inspect and verify illustrations
right on your computer.


Software and Format. All figures of accepted manuscripts should be in
TIFF or EPS formats.
Resolution. The minimum requirements for resolution are:
1200 DPI/PPI for black and white images, such as line drawings or graphs.
300 DPI/PPI for picture-only photographs
600 DPI/PPI for photographs containing pictures and line elements, i.e.,
text labels, thin lines, arrows.
These resolutions refer to the output size of the file; if you
anticipate that your images will be enlarged or reduced, resolutions
should be adjusted accordingly.
Color Art. Resolution should be at least 300 dpi for all color figures.
Files must be in CMYK format.
File names. Illustration files should be named by the figure number and
the 3-letter extension that identifies the file format used (i.e., .tif,
.eps).
Return to Top <#top>


            Charges


            Page Charges

There is no fee for the first 8 pages of an article. A fee of US$150.00
for each page beyond the first 8 will be charged. (To calculate the
number of printed pages your manuscript will become, count the number of
text pages, allowing a page for each table and figure, and divide the
total by 3. This gives a rough estimate.)
Return to Top <#top>


            Color Charges

Please be aware that the cost of color printing will be incurred by the
author. The color fee is US$500 per page.
Return to Top <#top>


            Notice of Wiley?s Compliance with NIH Grants and Contracts
            Policy


Recently, the National Institutes of Health (NIH) has requested that its
grantees submit copies of manuscripts upon their acceptance for
publication to PubMedCentral (PMC), a repository housed within the
National Library of Medicine. On behalf of our authors who are also NIH
grantees, Wiley will deposit in PMC at the same time that the article is
published in our journal the peer-reviewed version of the author's
manuscript. Wiley will stipulate that the manuscript may be available
for "public access" in PMC 12 months after the date of publication. By
assuming this responsibility, Wiley will ensure that authors are in
compliance with the NIH request, as well as make certain the appropriate
version of the manuscript is deposited. When an NIH grant is mentioned
in the Acknowledgments or any other section of a manuscript, Wiley will
assume that the author wants the manuscript deposited into PMC, unless
the author states otherwise. The author can communicate this via email,
or a note in the manuscript. The version of the manuscript that Wiley
sends to PMC will be the accepted version, i.e. the version that the
journal's Editor-in-Chief sends to Wiley for publication. Wiley will
notify the author when the manuscript has been sent to PMC. Because
Wiley is taking the responsibility for sending the manuscripts to PMC,
in order to ensure an orderly process, authors should not deposit Wiley
articles to PMC themselves. Authors should not make corrections to their
Wiley-deposited manuscripts in PMC. Wiley reserves the right to change
or rescind this policy. For further information, please get in touch
with your editorial contact at Wiley, or see the NIH Policy on Public
Access, located at: http://www.nih.gov/about/publicaccess/ .


            Contact Information

We invite inquiries to the editorial office at any time during the
editorial process. For all matters concerning presubmission, editorial
policies and procedures, and general production matters, please contact
the Heidelberg editorial office. Specific questions regarding your
proofs and copy editing of your manuscript can be handled by the
publisher, Wiley-Liss, Inc., in Hoboken. You can reach the publisher's
production department at ijcprod@wiley.com <mailto:ijcprod@wiley.com>

Footnotes
1
Davidoff F, DeAngelis CD, Drazen JM, Nicholls MG, Hoey J, Hojgaard L,
Horton R, Kotzin S, Nylenna M, Overbeke AJ, Sox HC, Van Der Weyden MB,
Wilkes MS. Sponsorship, authorship, and accountability. N Engl J Med
2001;345:825-6.
2
International Committee of Medical Journal Editors. Uniform requirements
for manuscripts submitted to biomedical journals. Ann Intern Med
1997;126:36-47. Update 2005 available at http://www.ICMJE.org
3
National Library of Medicine. List of journals indexed in index medicus.
Washington, DC: US Government Printing Office [published annually].

	


      /Search/ in this Title

International Journal of Cancer

Enter words or phrases
Select a Field


      /Search/ by Citation

Vol:
Issue:
Page:
Go <javascript:doCitationSearch();>
 


      /SEARCH/ WILEY INTERSCIENCE

All Content
Publication Titles
<http://www3.interscience.wiley.com/nojs.html>

    * Advanced Search <http://www3.interscience.wiley.com/search/allsearch>
    * CrossRef / Google Search
      <http://www3.interscience.wiley.com/crossref.html>
    * Acronym Finder
      <javascript:do_popup('http://www3.interscience.wiley.com/stasa/search.html')>


      /Special Features/

    * Highlighted Papers </journal/29331/home/highlighted_papers.htm>
    * Mission Statement </journal/29331/home/mission_statement.htm>
    * Other Resources </journal/29331/home/other_resources.htm>
    * SPECIAL SECTION ON CHRONIC OXIDATIVE STRESS AND INFLAMMATION: ROLE
      IN HUMAN CANCER DEVELOPMENT
      <http://www3.interscience.wiley.com/cgi-bin/jissue/116323782>
    * SPECIAL SECTION ON THE ROLE OF MICRORNAS IN HUMAN CANCER
      <http://www3.interscience.wiley.com/cgi-bin/jissue/117871866>


          Sign Up Now

Wiley InterScience MobileEdition
<http://www.wiley.com/trackthrough?urlcode=66850692>

Get select content from some of Wiley's leading publications delivered
to your PDA ? free!

Sign up now <http://www.wiley.com/trackthrough?urlcode=66850692>


          Reprint Inquiries

Wiley InterScience Article Reprints
<http://www.wiley.com/trackthrough?urlcode=Reprints_DOI>


            Need a reprint?


Paper or electronic reprints are available for all content published on
Wiley InterScience. Inquiries can be submitted online.

Find out more about reprints
<http://www.wiley.com/trackthrough?urlcode=Reprints_DOI>


          also-of-interest

EBM Guidelines <http://www.wiley.com/trackthrough?urlcode=456089>	

*EBM Guidelines*

*(Evidence-Based Medicine)*

The *key* source of practical information for primary care with the most
extensive collection of concise treatment recommendations

<http://www.wiley.com/trackthrough?urlcode=456089>

more <http://www.wiley.com/trackthrough?urlcode=456089>


          Also of Interest

Current Protocols cover image <
http://www.wiley.com/trackthrough?urlcode=456210>	

* Current Protocols in Cell Biology *

Updated every three months, an essential reference for methods for
researchers who study the cell - its structure, organization, behavior,
and functions.

Now available via individual online subscription!

Go to *Current Protocols
in Cell Biology* < http://www.wiley.com/trackthrough?urlcode=456210>


          Also of Interest

Current Protocols cover image <
http://www.wiley.com/trackthrough?urlcode=456220>	

* Current Protocols in Toxicology *

A "best-practices" collection of lab protocols for accurate, efficient
assessments of toxicity in whole organisms, organs and tissues, cells,
and biochemical pathways.

Now available via individual online subscription!

Go to *Current Protocols
in Toxicology* < http://www.wiley.com/trackthrough?urlcode=456220>

About Wiley InterScience </aboutus/> |  About Wiley
<http://www.wiley.com/go/about> |  Privacy </privacy.html> |  Terms &
Conditions </tacou.html>
Copyright <http://www.wiley.com/copyright> © 1999-2008 John Wiley &
Sons, Inc. <http://www.wiley.com> All Rights Reserved.
